The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial
Open accessAbstract
Importance: Ubrogepant is an oral calcitonin gene-related peptide receptor antagonist under investigation for acute treatment of migraine. Objective: To evaluate the efficacy and tolerability of ubrogepant compared with placebo for acute treatment of a single migraine attack. Design, Setting, and Participants: Phase 3, multicenter, randomized, double-blind, placebo-controlled, single-attack, clinical trial (ACHIEVE II) conducted in the United States (99 primary care and research clinics; August 26, 2016-February 26, 2018). Participants were adults with migraine with or without aura experiencing 2 to 8 migraine attacks per month. Interventions: Ubrogepant 50 mg (n = 562), ubrogepant 25 mg (n = 561), or placebo (n = 563) for a migraine attack of moderate or severe pain intensity. Main Outcomes and Measures: Co-primary efficacy outcomes were pain freedom and absence of the participant-designated most bothersome migraine-associated symptom (among photophobia, phonophobia, and nausea) at 2 hours after taking the medication. Results: Among 1686 randomized participants, 1465 received study treatment (safety population; mean age, 41.5 years; 90% female); 1355 of 1465 (92.5%) were evaluable for efficacy. Pain freedom at 2 hours was reported by 101 of 464 participants (21.8%) in the ubrogepant 50-mg group, 90 of 435 (20.7%) in the ubrogepant 25-mg group, and 65 of 456 (14.3%) in the placebo group (absolute difference for 50 mg vs placebo, 7.5%; 95% CI, 2.6%-12.5%; P = .01; 25 mg vs placebo, 6.4%; 95% CI, 1.5%-11.5%; P = .03). Absence of the most bothersome associated symptom at 2 hours was reported by 180 of 463 participants (38.9%) in the ubrogepant 50-mg group, 148 of 434 (34.1%) in the ubrogepant 25-mg group, and 125 of 456 (27.4%) in the placebo group (absolute difference for 50 mg vs placebo, 11.5%; 95% CI, 5.4%-17.5%; P = .01; 25 mg vs placebo, 6.7%; 95% CI, 0.6%-12.7%; P = .07). The most common adverse events within 48 hours of any dose were nausea (50 mg, 10 of 488 [2.0%]; 25 mg, 12 of 478 [2.5%]; and placebo, 10 of 499 [2.0%]) and dizziness (50 mg, 7 of 488 [1.4%]; 25 mg, 10 of 478 [2.1%]; placebo, 8 of 499 [1.6%]). Conclusions and Relevance: Among adults with migraine, acute treatment with ubrogepant compared with placebo led to significantly greater rates of pain freedom at 2 hours with 50-mg and 25-mg doses, and absence of the most bothersome migraine-associated symptom at 2 hours only with the 50-mg dose. Further research is needed to assess the effectiveness of ubrogepant against other acute treatments for migraine and to evaluate the long-term safety of ubrogepant among unselected patient populations. Trial Registration: ClinicalTrials.gov Identifier: NCT02867709.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Migraine prevalence, disease burden, and the need for preventive therapy
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007) · Neurology · doi:10.1212/01.wnl.0000252808.97649.21 · Cited by 2,337
Self-citationFeigin, V. L., Abajobir, A. A., Abate, K. H., Abd-Allah, F., Abdulle, A. M., Abera, S. F., Abyu, G. Y., Ahmed, M. B., Aichour, A. N., Aichour, I., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30299-5 · Cited by 2,275
Bigal, M. E., Serrano, D., Buse, D., Scher, A., Stewart, W. F., & Lipton, R. B. (2008) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2008.01217.x · Cited by 845
Self-citationMarmura, M. J., Silberstein, S. D., & Schwedt, T. J. (2015) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12499 · Cited by 568
American Headache Society (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13456 · Cited by 567
Ho, T. W., Ferrari, M. D., Dodick, D. W., Galet, V., Kost, J., Fan, X., Leibensperger, H., Froman, S., Assaid, C., Lines, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61626-8 · Cited by 531
Self-citationCGRP and its receptors provide new insights into migraine pathophysiology
Ho, T. W., Edvinsson, L., & Goadsby, P. J. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.127 · Cited by 523
Ho, T. W., Mannix, L. K., Fan, X., Assaid, C., Furtek, C., Jones, C. J., Lines, C. R., & Rapoport, A. M. (2008) · Neurology · doi:10.1212/01.wnl.0000286940.29755.61 · Cited by 464
A graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
Croop, R., Goadsby, P. J., Stock, D. A., Conway, C. M., Forshaw, M., Stock, E. G., Coric, V., & Lipton, R. B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31606-x · Cited by 403
Self-citationRimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
Lipton, R. B., Croop, R., Stock, E. G., Stock, D. A., Morris, B. A., Frost, M., Dubowchik, G. M., Conway, C. M., Coric, V., & Goadsby, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811090 · Cited by 398
Self-citationPsychiatric comorbidities of episodic and chronic migraine
Buse, D. C., Silberstein, S. D., Manack, A. N., Papapetropoulos, S., & Lipton, R. B. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6725-x · Cited by 395
Self-citationHy's law: predicting serious hepatotoxicity
Temple, R. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1211 · Cited by 352
Hewitt, D. J., Aurora, S. K., Dodick, D. W., Goadsby, P. J., Ge, Y. (., Bachman, R., Taraborelli, D., Fan, X., Assaid, C., Lines, C., et al. (2011) · Cephalalgia · doi:10.1177/0333102411398399 · Cited by 263
Self-citationVoss, T., Lipton, R. B., Dodick, D. W., Dupre, N., Ge, J. Y., Bachman, R., Assaid, C., Aurora, S. K., & Michelson, D. (2016) · Cephalalgia · doi:10.1177/0333102416653233 · Cited by 247
Self-citationRandomized, controlled trial of telcagepant for the acute treatment of migraine
Connor, K. M., Shapiro, R. E., Diener, H. C., Lucas, S., Kost, J., Fan, X., Fei, K., Assaid, C., Lines, C., & Ho, T. W. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b87942 · Cited by 217
Lipton, R. B., Buse, D. C., Serrano, D., Holland, S., & Reed, M. L. (2013) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12154 · Cited by 164
Self-citationPharmacoepidemiology and Drug Safety
Boshier, A., Shakir, S. A. W., Telfer, P. T., Behr, E., Pakrashi, T., & Camm, A. J. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/(issn)1099-1557 · Cited by 136
Risk of medication overuse headache across classes of treatments for acute migraine
Thorlund, K., Sun‐Edelstein, C., Druyts, E., Kanters, S., Ebrahim, S., Bhambri, R., Ramos, É., Mills, E. J., Lantéri‐Minet, M., & Tepper, S. J. (2016) · The Journal of Headache and Pain · doi:10.1186/s10194-016-0696-8 · Cited by 127
Satisfaction With Current Migraine Therapy: Experience From 3 Centers in US and Sweden
BIGAL, M. E., Rapoport, A. M., Aurora, S. K., Sheftell, F. D., Tepper, S. J., & Dahlöf, C. G. H. (2007) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2007.00752.x · Cited by 98
Cady, R. K., McAllister, P. J., Spierings, E. L. H., Messina, J. C., Carothers, J. L., Djupesland, P. G., & Mahmoud, R. A. (2014) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12472 · Cited by 68
Lipton, R. B., Reed, M. L., Kurth, T., Fanning, K. M., & Buse, D. C. (2017) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13179 · Cited by 61
Self-citation
Cited by
Ashina, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1915327 · Cited by 816
Ailani, J., Burch, R. C., Robbins, M. S., & the Board of Directors of the American Headache Society (2021) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.14153 · Cited by 766
Self-citationDiagnosis and management of migraine in ten steps
Eigenbrodt, A. K., Ashina, H., Khan, S., Diener, H.-C., Mitsikostas, D. D., Sinclair, A. J., Pozo-Rosich, P., Martelletti, P., Ducros, A., Lantéri-Minet, M., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00509-5 · Cited by 594
Ferrari, M. D., Goadsby, P. J., Burstein, R., Kurth, T., Ayata, C., Charles, A., Ashina, M., van den Maagdenberg, A. M. J. M., & Dodick, D. W. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00328-4 · Cited by 500
Self-citationHautakangas, H., Winsvold, B. S., Ruotsalainen, S. E., Bjornsdottir, G., Harder, A. V. E., Kogelman, L. J. A., Thomas, L. F., Noordam, R., Benner, C., Gormley, P., et al. (2022) · Nature Genetics · doi:10.1038/s41588-021-00990-0 · Cited by 398
Metadata
- Authors
- Lipton, R. B., Dodick, D. W., Ailani, J., Lu, K., Finnegan, M., Szegedi, A., & Trugman, J. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2019-11-19
- Volume
- 322
- Issue
- 19
- Pages
- 1887
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2990037077
- Cited by
- 279
- References
- 26
- FWCI
- 27.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.